Literature DB >> 15354393

Transdermal lisuride delivery in the treatment of Parkinson's disease.

D Woitalla1, T Müller, S Benz, R Horowski, H Przuntek.   

Abstract

Transdermal delivery of dopamine agonists (DA) is a promising therapeutic concept, which aims to ameliorate frequency and intensity of motor fluctuations in patients with Parkinson's disease (PD). We treated 8 PD patients with unpredictable on-off phenomena with lisuride patches (release: 2-5 microg lisuride base/cm2/hour in mice) in addition to their preexisting antiparkinsonian drug regime up to a period of 8 days. In order to quantify the intensity and frequency of motor fluctuations, we determined the motor changing rate (MCR), which corresponds to the patient's self rating of motor function, performed every thirty minutes, divided through the number of scored intervals minus 1. Additional lisuride patch application significantly (p = 0.023) improved the MCR compared to baseline. Relevant side effects were transient skin irritations in four patients. Our observational study demonstrates the safety, tolerability and efficacy of transdermal lisuride delivery in the treatment of motor complications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354393     DOI: 10.1007/978-3-7091-0579-5_10

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  7 in total

Review 1.  A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

Authors:  R Horowski
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 2.  Classical dopamine agonists.

Authors:  R Horowski; P-A Löschmann
Journal:  J Neural Transm (Vienna)       Date:  2019-02-25       Impact factor: 3.575

Review 3.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Use of transdermal drug formulations in the elderly.

Authors:  Laure-Zoé Kaestli; Anne-Florence Wasilewski-Rasca; Pascal Bonnabry; Nicole Vogt-Ferrier
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

Authors:  Joseph Jankovic; Mark Stacy
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

Review 7.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.